This is a summary of results from a phase 3 clinical study called HIMALAYA. HIMALAYA looked at treatment with one dose of a medication called tremelimumab combined with multiple doses of a medication called durvalumab (the STRIDE regimen) or multiple doses of durvalumab alone. These treatments were compared with a medication called sorafenib in participants with unresectable hepatocellular carcinoma (HCC).HCC is a type of liver cancer that is difficult to treat because it is often diagnosed when it is unresectable, meaning it can no longer be removed with surgery. Sorafenib has been the main treatment for unresectable HCC since 2007. However, people who take sorafenib may experience side effects that can reduce their quality of life, so alternative medicines are being trialed. Tremelimumab and durvalumab are types of drugs called immunotherapies, and they both work in different ways to help the body’s immune system fight cancerThis Plain Language Summary of Publication article from Future Oncology describes the results of a study called HIMALAYA. Unresectable hepatocellular carcinoma (HCC) is a type of liver cancer that is difficult to treat because it is often diagnosed when it is unresectable, meaning it can no longer be removed with surgery. HIMALAYA looked at treatment with one dose of a medication called tremelimumab combined with multiple doses of a medication called durvalumab (the STRIDE regimen) or multiple doses of durvalumab alone.

Please visit Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma’ and was published in the New England Journal of Medicine Evidence. 

Please visit the New England Journal of Medicine Evidence using the link to read the article.